Analysts See $-0.73 EPS for BeyondSpring Inc. (BYSI)

May 17, 2018 - By Jason Grubb

Analysts expect BeyondSpring Inc. (NASDAQ:BYSI) to report $-0.73 EPS on May, 28.They anticipate $1.93 EPS change or 72.56 % from last quarter’s $-2.66 EPS. After having $-0.68 EPS previously, BeyondSpring Inc.’s analysts see 7.35 % EPS growth. The stock increased 0.51% or $0.14 during the last trading session, reaching $27.74. About 9,573 shares traded. BeyondSpring Inc. (NASDAQ:BYSI) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company has market cap of $622.92 million. The firm is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. It currently has negative earnings.

More recent BeyondSpring Inc. (NASDAQ:BYSI) news were published by: Globenewswire.com which released: “BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting” on April 25, 2018. Also Nasdaq.com published the news titled: “BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the …” on May 17, 2018. Nasdaq.com‘s news article titled: “BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference” with publication date: May 07, 2018 was also an interesting one.

BeyondSpring Inc. (NASDAQ:BYSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.